Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

40.73 -0.10 (-0.26%)

Streaming Delayed Price Updated: 2:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

April 01, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. ↗

March 29, 2024

In the world of growth stocks, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shines as a value proposition.

Via Chartmill

Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation. ↗

March 07, 2024

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

Via Chartmill

What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday? ↗

February 16, 2024

Findings of Corcept Therapeutics' CATALYST study on Cushing's syndrome & difficult-to-control type 2 diabetes.

Via Benzinga

Recap: Corcept Therapeutics Q4 Earnings ↗

February 15, 2024

Via Benzinga

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Earnings Preview: Corcept Therapeutics ↗

February 14, 2024

Via Benzinga

Despite its growth, NASDAQ:CORT remains within the realm of affordability. ↗

January 03, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:CORT.

Via Chartmill

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

December 05, 2023

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.

Via Chartmill

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

February 15, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

February 15, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗

February 14, 2024

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.

Via Chartmill

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

February 08, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Where Corcept Therapeutics Stands With Analysts ↗

November 06, 2023

Via Benzinga

Corcept Appoints Roberto Vieira as President, Oncology

January 29, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗

January 24, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued.

Via Chartmill

Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

January 22, 2024

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Daniels-Midland Company (NYSE: ADM) fell sharply in today’s pre-market trading...

Via Benzinga

Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

January 08, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Crude Oil Down 2%; Tesla Deliveries Top Estimates ↗

January 02, 2024

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded up 0.01% to 37,691.77 while the NASDAQ fell 1.78% to...

Via Benzinga

Topics Stocks

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 02, 2024

Shares of Longboard Pharmaceuticals, Inc.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 02, 2024

Via Benzinga

Dow Turns Higher; Anavex Life Sciences Shares Plunge ↗

January 02, 2024

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.13% to 37,739.18 while the NASDAQ fell 1.29% to 14,818.23. The S&P 500...

Via Benzinga

Topics Stocks

Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday ↗

January 02, 2024

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Tuesday.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 02, 2024

Via Benzinga

Court Finds Corcept Therapeutics’ Patents Not Infringed

January 02, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January ↗

January 02, 2024

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 01, 2024

Via Benzinga

In the world of growth stocks, NASDAQ:CORT shines as a value proposition. ↗

November 10, 2023

Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗

November 09, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

Via InvestorPlace

Topics Economy

Clorox To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 02, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

All News about Corcept Therapeutics Incorporated - Common Stock

Starting at $3.75/week.

Subscribe Today